The analysis also found no statistically significant difference in the risk of NAION—non-arteritic anterior ischaemic optic ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...